Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

Educational information

This video was recorded at the ESC Heart Failure in Athens, Greece, on May 26, 2019 and is a short reproduction of his presentation during the Late Breaking trial II - Chronic Heart Failure session.

Faculty

Patrick Rossignol, MD, PhD is nephrologist, professor in Therapeutics and expert in hypertension. He is a physician at the Clinical Investigation Centre Inserm (CIC) at Nancy, France

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Read our summary of the AMBER trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.